Agios Pharmaceuticals Strengthens Leadership with New Appointment
Agios Pharmaceuticals, Inc. (Nasdaq: AGIO) is making headlines with the recent addition of Dr. Jay Backstrom to its Board of Directors. This strategic move comes as Agios aims to elevate its clinical programs and further its mission in the realm of rare diseases. Dr. Backstrom, MD, MPH, is recognized for his extensive experience and success in navigating the complexities of clinical advancements and regulatory approvals.
Welcome Statement from Agios Leadership
Brian Goff, the Chief Executive Officer of Agios, expressed enthusiasm regarding Dr. Backstrom's appointment. He stated, "We are thrilled to welcome Jay to the Agios Board of Directors. His deep scientific insight, extensive regulatory expertise, and strategic business leadership come at a pivotal time for Agios. This coincides with our efforts to maximize the potential of PYRUKYND (mitapivat), our groundbreaking PK activator, and our expanding portfolio of rare disease treatments."
Dr. Backstrom’s Impressive Track Record
Dr. Backstrom's healthcare leadership spans various sectors, from large pharmaceutical companies to agile biotech firms and early-stage biopharma organizations. His recent tenure as President and CEO of Scholar Rock showcased his ability to navigate complex clinical challenges, particularly in advancing the company's lead program targeting spinal muscular atrophy through critical phases of development and essential regulatory submissions within both the U.S. and European markets.
Previously, he held significant roles, including Executive Vice President at Acceleron Pharma, acquired by Merck in 2021, and Chief Medical Officer at Celgene Corporation. At Celgene, Dr. Backstrom made significant contributions to broadening the company’s pipeline of therapeutics, overseeing critical clinical programs that led to vital regulatory approvals in conditions like beta thalassemia and myelodysplastic syndromes.
A Vision for the Future
Expressing his enthusiasm, Dr. Backstrom commented, "It is an honor to join Agios’ Board of Directors and work alongside such a talented group as the company enters its next phase of commercial growth and innovation. Agios is laser-focused on redefining the future of rare disease treatment, driven by a maturing and expanding pipeline of promising innovative medicines. Having followed the company’s progress and collaborated with several members of the leadership team and Board in the past, I am eager to contribute to advancing its inspiring mission.”
Agios’ Commitment to Rare Disease Therapies
Agios continues to stand at the forefront of PK activation, with a devoted commitment to developing therapies that profoundly impact the lives of patients battling rare diseases. Making strides in healthcare innovation, Agios currently markets a pioneering PK activator designed for adults with PK deficiency. This marks a historical milestone as the first disease-modifying therapy for a condition characterized by long-term, debilitating anemia.
The company’s research embodies a deep understanding of classical hematology and its applications to cellular metabolism and rare hematologic disorders. Agios is actively cultivating a robust clinical pipeline aimed at addressing conditions such as alpha- and beta-thalassemia, sickle cell disease, pediatric PK deficiency, and myelodysplastic syndromes (MDS)-associated anemia. Moreover, an exciting avenue of exploration includes a preclinical TMPRSS6 siRNA, envisioned as a potential treatment for polycythemia vera.
Connect with Agios
In its mission to innovate rare disease therapies, Agios represents a beacon of hope for patients and families affected by these conditions. For those interested in learning more about Agios and its offerings, please visit the company’s official website.
Frequently Asked Questions
Who is Dr. Jay Backstrom?
Dr. Jay Backstrom is a healthcare executive with decades of experience leading clinical programs and regulatory strategies.
What is PYRUKYND?
PYRUKYND (mitapivat) is Agios’ first-in-class PK activator designed to treat patients with PK deficiency.
What is Agios' focus in rare diseases?
Agios is dedicated to developing innovative therapies for rare diseases, with a robust pipeline aimed at various hematologic conditions.
What role will Dr. Backstrom serve on the Board?
Dr. Backstrom will be part of Agios’ Science and Technology Committee, contributing to the company’s strategic development.
How can I get more information about Agios?
For further information, interested individuals can visit Agios' official website or contact their investor relations department directly.
